RHEACELL GmbH & Co. KG

TICEBA founds subsidiary RHEACELL.

TICEBA - Company - RHEACELL GmbH & Co. KG - Picture 01TICEBA - Company - RHEACELL GmbH & Co. KG - Picture 02

 

RHEACELL is dedicated to the development of human pharmaceuticals based on ABCB5-positive mesenchymal skin stem cells. For selected indications RHEACELL strives for improvement of quality of life as well as abatement and healing of ailments of patients.

TICEBA contributes its established know-how as well as its qualified employees to the success of the development of pharmaceuticals of RHEACELL.

Please click HERE for more information on RHEACELL.

TICEBA - Company - RHEACELL GmbH & Co. KG - Picture 03

News
License

Besides the authorization to manufacture a human medicinal product in accordance with § 13 (1) of the German Medicinal Products Act (AMG) for autologous mesenchymal stem cells, TICEBA is also authorized to manufacture a medicinal product for allogeneic mesenchymal as well as allogeneic limbal ABCB5 + stem cells following a recent extension. For more information click HERE.

Clinical Trial

Together with our subsidiary RHEACELL we are recruiting patients with the indication chronic venous ulcer (CVU) for the clinical trial in phase 1/2a. For more information click HERE.

The Story of Stem Cells

Review our category "The Story of Stem Cells" with the newest topic "Stem cells in wound healing" HERE.

Newsletter